JNJ: JNJ4804 Despite likely efficacy, maintenance Rx concerns over combo in UC
The market continues to underestimate Imaavy's prospects from...
JNJ: New Imaavy faces headwinds from Myasthenia incumbents but promising in other FcRn markets
The market continues to underestimate Imaavy's prospects from...
VERA: IgAN: Atacicept phase III ORIGIN3: likely positive
Ahead of VERA’s upcoming ORGIN3 IgA nephropathy trial in 2Q25, our analysis suggests a positive Phase III outcome that is in line with...
JNJ/PTGX: JNJ2113: Icotrokinra ANTHEM-Ulercative Colitis efficacy similar to oral competitors
Despite headline efficacy in PTGX/JNJ's ulcerative colitis phase 2 ANTHEM-UC at its highest dose, the initial efficacy appears similar to...
JNJ/PTGX: JNJ2113: Concerns over upcoming (Q1) oral IL23 ANTHEM trial in Ulcerative Colitis
With JNJ2113's (icotrokinra) upcoming ulcerative colitis ANTHEM-UC trial reading out this first quarter, our unique UC specific analysis...
NOVN: Consensus missing large Fabhalta upside
The market continues to underestimate Fabhalta's prospects from current and potential indications. The recent positive APPULSE trial...
